Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 An analysis of dosage volume for halfway doses in the Victoza Pen.

× No keyword cloud information.

8 in total

1. Accuracy of dosage volume for halfway doses in the Victoza Pen.

Authors: Allen B King; Gary S Wolfe
Journal: J Diabetes Sci Technol Date: 2011-11-01

2. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

Authors: Tina Vilsbøll; Milan Zdravkovic; Tu Le-Thi; Thure Krarup; Ole Schmitz; Jean-Pierre Courrèges; Robert Verhoeven; Ingrid Bugánová; Sten Madsbad
Journal: Diabetes Care Date: 2007-03-19 Impact factor: 19.112

3. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Authors: Alan Garber; Robert Henry; Robert Ratner; Pedro A Garcia-Hernandez; Hiromi Rodriguez-Pattzi; Israel Olvera-Alvarez; Paula M Hale; Milan Zdravkovic; Bruce Bode
Journal: Lancet Date: 2008-09-24 Impact factor: 79.321

4. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

Authors: John B Buse; Julio Rosenstock; Giorgio Sesti; Wolfgang E Schmidt; Eduard Montanya; Jason H Brett; Marcin Zychma; Lawrence Blonde
Journal: Lancet Date: 2009-06-08 Impact factor: 79.321

5. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.

Authors: D Russell-Jones; A Vaag; O Schmitz; B K Sethi; N Lalic; S Antic; M Zdravkovic; G M Ravn; R Simó
Journal: Diabetologia Date: 2009-08-14 Impact factor: 10.122

6. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

Authors: M Marre; J Shaw; M Brändle; W M W Bebakar; N A Kamaruddin; J Strand; M Zdravkovic; T D Le Thi; S Colagiuri
Journal: Diabet Med Date: 2009-03 Impact factor: 4.359

7. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

Authors: Bernard Zinman; John Gerich; John B Buse; Andrew Lewin; Sherwyn Schwartz; Philip Raskin; Paula M Hale; Milan Zdravkovic; Lawrence Blonde
Journal: Diabetes Care Date: 2009-03-16 Impact factor: 17.152

8. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Authors: Michael Nauck; Anders Frid; Kjeld Hermansen; Nalini S Shah; Tsvetalina Tankova; Ismail H Mitha; Milan Zdravkovic; Maria Düring; David R Matthews
Journal: Diabetes Care Date: 2008-10-17 Impact factor: 17.152

8 in total